Page 59 - SPEMD_62-3

rev port estomatol med dent cir maxilofac . 2021;62(3):181-185 185

2. Fakoya AOJ, Omenyi P, Anthony P, Anthony F, Etti P, Otohinoyi 9. Bulisani ACP, Sanches GD, Guimarães HP, Lopes RD,
DA, et al. Stevens-Johnson Syndrome and Toxic Epidermal Vendrame LS, Lopes AC. Síndrome de Stevens-Johnson e
Necrolysis; Extensive Review of Reports of Drug-Induced necrólise epidérmica tóxica em medicina intensiva. Rev Bras
Etiologies, and Possible Therapeutic Modalities. Open Access Ter Intensiva. 2006;18:292-7.
Maced J Med Sci. 2018;6:730-8. 10. Köstler WJ, Hejna M, Wenzel C, Zielinski CC. Oral mucositis
3. Carrasquillo OY, Santiago-Vazquez M, Cardona R, Cruz- complicating chemotherapy and/or radiotherapy: options
Manzano M, Figueroa LD. Stevens-Johnson syndrome and for prevention and treatment. CA Cancer J Clin.
toxic epidermal necrolysis: a retrospective descriptive study. 2001;51:290-315.
Int J Dermatol. 2019;58:1293-9. 11. Gonzalez-Moles MA, Morales P, Rodriguez-Archilla A, Isabel
4. Nühnen VP, Schön MP, Mössner R. Stevens-Johnson syndrome/ IR, Gonzalez-Moles S. Treatment of severe chronic oral
toxic epidermal necrolysis overlap in a NSCLC patient treated erosive lesions with clobetasol propionate in aqueous
with afatinib. J Dtsch Dermatol Ges. 2018;16:199-201. solution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod.
5. Doesch J, Debus D, Meyer C, Papadopoulos T, Schultz ES, 2002;93:264-70.
Ficker JH, et al. Afatinib-associated Stevens-Johnson 12. Cronshaw M, Parker S, Anagnostaki E, Mylona V, Lynch E,
syndrome in an EGFR-mutated lung cancer patient. Lung Grootveld M. Photobiomodulation and Oral Mucositis: A
Cancer. 2016;95:35-8. Systematic Review. Dent J (Basel). 2020;8:87.
6. Oda T, Sawada Y, Ohmori S, Omoto D, Haruyama S, Yoshioka 13. Simões A, Freitas PM, Bello-Silva MS, Tunér J, Eduardo CP.
M, et al. Fixed drug eruption-like macules caused by Laser phototherapy for Stevens-Johnson syndrome: a case
febuxostat. Eur J Dermatol. 2016;26:412-3. report. Photomed Laser Surg. 2011;29:67-9.
7. Marinis F, Catania C, Passaro A. Afatinib in NSCLC harbouring 14. Rocha AL, Souza AF, Nunes LFM, Cunha NDS, Lanza CRM,
EGFR mutations. Lancet Oncol. 2014;15:e148-9. Travassos DV, et al. Treatment of oral manifestations of
8. C Chen X, Zhu Q, Zhu L, Pei D, Liu Y, Yin Y, Schuler M, Shu Y. toxic epidermal necrolysis with low-level laser therapy in a
Clinical perspective of afatinib in non-small cell lung cancer. pediatric patient. Pediatr Dermatol. 2019;36:e27-e30.
Lung Cancer. 2013;81:155-61.